Clinical trialNCT07386002Not, yet, recruitingPhase 2Interventional

The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

SponsorT-MAXIMUM Pharmaceutical IncEnrollment40Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 \& Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kuo-Chen Wei, MD
Chang Gung Memorial Hospital
Principal Investigator
clinicaltrials.gov ↗
Solmaz Sahebjam, MD
The Johns Hopkins Cancer Center, Sibley Memorial Hospital
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Taiwan

Hualien Tzu Chi Hospital
Hualien City, Taiwan
Shinn-Zong Lin, MD, PhD
Chang Gung Memorial Hospital, Kaohsiung
Kaohsiung City, Taiwan
Fu-Yuan Shih, MD
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan
Kuo-Chen Wei, MD

United States

the Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Solmaz Sahebjam, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Jun 2026
Primary completion: 13 Dec 2028
Completion: 31 Jul 2029
Last update posted: 10 Feb 2026
Registered enrollment: 40
Registry id: NCT07386002

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.